Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.54 |
| ▸ | CYP51A1 | Q16850 | 5/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | FNTA | P49354 | 1/20 | 0.41 |
| ▸ | FNTB | P49356 | 1/20 | 0.41 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7561815 | 0.92 | PTGS2 (0.57) | PTGS2CYP51A1CYP19A1IDO1CYP3A4 | |
| SCHEMBL7561820 | 0.89 | PTGS2 (0.52) | PTGS2CYP51A1CYP19A1IDO1FNTA | |
| SCHEMBL7563092 | 0.85 | PTGS2 (0.52) | PTGS2CYP51A1CYP19A1IDO1CYP3A4 | |
| SCHEMBL7561152 | 0.82 | FNTA (0.51) | PTGS2CYP51A1FNTAFNTBPGGT1B | |
| SCHEMBL7605941 | 0.82 | PTGS2 (0.46) | PTGS2CYP51A1CYP19A1FNTAFNTB | |
| SCHEMBL7605945 | 0.82 | PTGS2 (0.48) | PTGS2CYP51A1CYP19A1FNTAFNTB | |
| SCHEMBL7563951 | 0.82 | PTGS2 (0.46) | PTGS2CYP19A1IDO1CYP3A4CYP2C9 | |
| SCHEMBL7563722 | 0.81 | FNTA (0.49) | PTGS2CYP51A1FNTAFNTBPGGT1B | |
| SCHEMBL7561742 | 0.81 | FNTA (0.49) | PTGS2CYP51A1FNTAFNTBPGGT1B | |
| SCHEMBL7569922 | 0.81 | PTGS2 (0.47) | PTGS2CYP51A1CYP19A1IDO1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020058665-A1 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors | ASTRAZENECA UK LIMITED | 2002-05-16 | — | — | US | disclosed |
| US-20020052376-A1 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors | ASTRAZENECA UK LIMITED | 2002-05-02 | — | — | US | disclosed |
| US-6342765-B1 | COMPOUNDS THAT INHIBIT FARNESYLATION OF MUTANT RAS GENE PRODUCTS; TREATING DISEASES, ESPECIALLY CANCER, WHICH ARE MEDIATED THROUGH FARNESYLATION OF RAS | ASTRAZENECA UK LIMITED (GB) | 2002-01-29 | — | — | US | disclosed |
| EP-1025088-B1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | ASTRAZENECA AB (SE) | 2001-09-05 | — | — | EP | disclosed |
| EP-1025088-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | AstraZeneca UK Limited (GB) | 2000-08-09 | — | — | EP | disclosed |
| WO-1999020611-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | ZENECA LIMITED (GB) | 1999-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058665-A1 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors | FNTA, FNTB, RABGGTA | PTGS2 2714/4885CYP51A1 75/4885CYP19A1 836/4885 |
| US-20020052376-A1 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors | FNTA, FNTB, RABGGTA | PTGS2 2763/4885CYP51A1 107/4885CYP19A1 806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.